IO Biotech, Inc. (IOBT) |
|
1.37 -0.01 (-0.72%)
|
10-02 15:59 |
|
Open: |
1.39 |
Pre. Close: |
1.38 |
|
High:
|
1.47 |
Low:
|
1.33 |
|
Volume:
|
20,698 |
Market Cap:
|
90(M) |
|
|
|
Technical analysis |
as of: 2023-10-02 4:20:59 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 2 One year: 2.37 |
| Support: |
Support1: 1.2 Support2: 0.99 |
| Resistance: |
Resistance1: 1.71 Resistance2: 2.02 |
| Pivot: |
1.39  |
| Moving Average: |
MA(5): 1.33 MA(20): 1.47
MA(100): 1.83 MA(250): 2.2 |
| MACD: |
MACD(12,26): -0.2  Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 28.4 %D(3): 20.8 |
| RSI: |
RSI(14): 37.1 |
| 52-week: |
High: 3.51 Low: 1.2 |
| Average Vol(K): |
3-Month: 130 (K) 10-Days: 47 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IOBT ] has closed above bottom band by 39.4%. Bollinger Bands are 32.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.47 - 1.48 |
1.48 - 1.49 |
|
Low:
|
1.31 - 1.32 |
1.32 - 1.33 |
|
Close:
|
1.36 - 1.37 |
1.37 - 1.38 |
|
Company Description |
|
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark. |
Headline News |
Thu, 28 Sep 2023
IO Biotech A Promising Future in Immune Therapies - Best Stocks
Tue, 12 Sep 2023
IO Biotech Announces New Data Related to its IO102-IO103 ... - GlobeNewswire
Wed, 06 Sep 2023
IO Biotech Announces Participation in Upcoming Investor Conferences - GlobeNewswire
Thu, 10 Aug 2023
Is IO Biotech Inc (IOBT) Stock a Smart Investment Thursday? - InvestorsObserver
Tue, 08 Aug 2023
Should You Hold IO Biotech Inc (IOBT) Stock Tuesday Morning? - InvestorsObserver
Fri, 28 Jul 2023
IO Biotech Announces First Patient Dosed in Investigator-Initiated ... - BioSpace
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
66 (M) |
| Shares Float |
27 (M) |
|
% Held by Insiders
|
6.4 (%) |
|
% Held by Institutions
|
77.8 (%) |
|
Shares Short
|
632 (K) |
|
Shares Short P.Month
|
421 (K) |
Stock Financials |
|
EPS
|
-2.61 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
3.63 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-31.7 |
|
Return on Equity (ttm)
|
-53.5 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.16 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-59 (M) |
|
Levered Free Cash Flow
|
-32 (M) |
Stock Valuations |
|
PE Ratio
|
-0.53 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.37 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.54 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
